EGFR and cancer: Our results indicatethat the sorafenib–ruthenium complexes exhibit superior epidermalgrowth factor receptor (EGFR) inhibition compared to sorafenib alone.Interestingly, among these complexes, Ru3S demonstratedhigh activity against various cancer cell lines including sorafenib-resistantHepG2 cells while exhibiting significantly lower cytotoxicity thansorafenib in healthy cell lines.